PT-141
Productby Palatin Technologies
Heard in 4 episodes across 4 shows since Aug 2026
PT-141 is the peptide drug bremelanotide, a melanocortin receptor agonist marketed as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 2 |
| Oct 2026 | 1 |
| Nov 2026 | 0 |
Email alert
Email me when PT-141 comes up on a podcast
One email a week at most, with the new episodes that mention PT-141. Free, no account needed, unsubscribe in one click.
What experts have said about PT-141
9 statements · 8 positive · 1 mixed
AO-252 reaches brain tissue at roughly blood-equivalent levels.
“Our ability to actually have pretty much on a 1-to-1 level of what the, the in the blood versus what's in the brain”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 11:03
AO-252 has an approximately 80% clinical benefit rate.
“our clinical benefit rate is at about 80%.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:08
AO-252 reduced a tumor by 30% in a heavily pretreated patient.
“it still takes 30% of the tumor down.”
Open the episode · S11 Ep68: Sunday Roast featuring Coiled Therapeutics PLC and Halo Resources #COIL #HALO #EPP #DELTA #KEN #AEGListen at 13:41
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
4 episodes featuring PT-141, newest first
- Oct 16, 2026
Peptide therapy meets personalized care and entrepreneurial riskWake Up to WealthOct 16, 2026 - Sep 9, 2026
A near-fatal surgery reshaped Mark Hyman’s view of healthThe Dr. Hyman ShowSep 9, 2026 - Sep 1, 2026
Testosterone enters the menopause conversationunPAUSED with Dr. Mary Claire HaverSep 1, 2026 - Aug 8, 2026
Biohackers challenge the stigma around performance enhancementThe Dylan Gemelli PodcastAug 8, 2026